NanoString Technologies, Inc. (NSTG)
(Delayed Data from NSDQ)
$27.96 USD
+0.86 (3.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $27.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$27.96 USD
+0.86 (3.17%)
Updated May 3, 2019 04:00 PM ET
After-Market: $27.94 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Can GW Pharmaceuticals (GWPH) Deliver a Beat in Q1 Earnings?
by Zacks Equity Research
On GW Pharmaceuticals' (GWPH) first-quarter fiscal 2019 conference call, investor focus will be on the initial sales uptake of its newly approved anti-epileptic drug, Epidiolex.
Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?
by Zacks Equity Research
Within Hip business, we expect Zimmer Biomet (ZBH) to experience a strong uptick in the Asia-Pacific region.
Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings?
by Zacks Equity Research
IDEXX (IDXX) is expected to keep its momentum alive in Q4, banking on a strong global rise in Companion Animal Group Diagnostics' revenues.
Will Overall Growth Aid Thermo Fisher's (TMO) Q4 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) rides high on a steadily strong analytical instrument business, flaunting robust global demand.
Can Solid Consumables Drive Illumina's (ILMN) Q4 Earnings?
by Zacks Equity Research
Illumina's (ILMN) management is optimistic about witnessing solid demand across the NovaSeq portfolio, which also includes the S2 and S1 flow cells.
NanoString Technologies, Inc. (NSTG) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in NanoString Technologies, Inc. (NSTG).
What Lies Ahead for Abbott (ABT) Stock This Earnings Season?
by Zacks Equity Research
Abbott (ABT) is showing a steady rise on a healthy growth graph within its Diabetes Care business for a considerable period.
4 Medical Product Stocks Likely to Top Q4 Earnings Estimates
by Zacks Equity Research
Given the encouraging performance of the medical products industry for most part of 2018, it will be interesting see how the constituent companies perform in Q4.
NanoString Technologies (NSTG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of 6.67% and 10.49%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
NanoString Technologies (NSTG) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
NanoString (NSTG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in NanoString Technologies (NSTG) Stock?
by Zacks Equity Research
Investors need to pay close attention to NanoString Technologies (NSTG) stock based on the movements in the options market lately.
NanoString Technologies (NSTG) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
NanoString (NSTG) delivered earnings and revenue surprises of -12.68% and -0.42%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Top Performing Stocks of the Best ETF of May
by Sweta Killa
Inside the best performing stocks of the top ETF of May - ARKG.
What Makes Nanostring Technologies (NSTG) a Strong Sell?
by Zacks Equity Research
Investors may consider dropping NanoString Technologies, Inc. (NSTG), that has not only witnessed a significant price decline in the past four weeks, but also has seen negative earnings estimate revisions.
Align Poised On Global Expansion & Invisalign Teen Growth
by Zacks Equity Research
On Jan 10, 2017, we issued an updated research report on California-based Align Technology Inc. (ALGN).
Illumina (ILMN) Launches NovaSeq Series for $100 Genome
by Zacks Equity Research
Illumina, Inc. (ILMN) recently unveiled the NovaSeq Series, a scalable sequencing solution expected to enable a $100 genome.
QIAGEN (QGEN) Buys OmicSoft, Expands Bioinformatics Suite
by Zacks Equity Research
QIAGEN N.V. (QGEN) recently announced the acquisition of Cary, NC-based OmicSoft Corporation.
LLabCorp: Reimbursement Scenario a Drag Amid Other Woes
by Zacks Equity Research
On Jan 09, we issued an updated research report on Burlington, NC-based Laboratory Corporation of America Holdings (LH) or LabCorp.
ResMed and Dr. Oz Form SleepScore Labs for Sleep Disorders
by Zacks Equity Research
ResMed Inc. (RMD) recently formed a joint venture with renowned surgeon and television host Dr. Mehmet Oz and private equity firm Pegasus Capital Advisors, L.P.
Myriad Genetics: Evidence Street Reviews EndoPredict Test
by Zacks Equity Research
Myriad Genetics, Inc. (MYGN) recently announced that Blue Cross Blue Shield Association's technical assessment provider Evidence Street has reviewed its EndoPredict assay.